ArticleScientific reports2026
Clinicopathological and imaging factors of surgical margin status and prognosis in breast-conserving therapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To identify factors influencing margins, re-excision rates, and prognosis in breast-conserving surgery (BCS) patients, and compare the accuracy of ultrasonography (US), mammography (MG), and magnetic resonance imaging (MRI) in assessing tumor size, axillary lymph node status and margins using pathology as the gold standard. A retrospective analysis was conducted on 2775 consecutive invasive breast cancer patients who receive BCS between June 2014 and June 2024. All patients underwent preoperative US, MG, and MRI. The positive margin rate was 18.2% (506/2775). Independent predictors of margin status included pT, lymphovascular invasion (LVI), extensive intraductal component (EIC), US-measured tumor size, MRI-based abnormal enhancement extent, fibroglandular tissue (FGT), background parenchymal enhancement (BPE), non-mass-like enhancement (NME), and axillary lymph node metastasis (ALNM). Factors influencing margin status varied significantly across MRI tumor size subgroups and molecular subtypes. US demonstrated the highest accuracy for preoperative tumor size assessment, while MRI outperformed other modalities in evaluating resection margin status and ALNM. Among 2,450 patients who successfully underwent BCS, the reoperation rate was independently associated with HER2, EIC, MRI abnormal enhancement extent, FGT, BPE, and ALNM. The local-regional recurrence (LRR) rate was 2.5%, with independent predictors including age, molecular subtype, LVI, EIC, MRI abnormal enhancement extent, BPE, ductal pattern orientation, and radiotherapy status. Preoperative imaging and molecular subtyping provide critical insights into margin status and recurrence risk in BCS patients. Tailored surgical planning and adjuvant therapy based on these factors may optimize clinical outcomes and reduce recurrence rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.